Deleted Tweets From Scott Gottlieb, R-D.C.

#FDA is seeking certain administrative steps to expand the strength of our regulatory oversight in the IMFs and may seek some additional, limited resources and authorities from Congress. We’re also working closely with our partners at @CBP & @USPS as

I’m committed to having clear implementation plans for our strategic goals & objectives while being as transparent as possible about our regulatory approach to food safety & nutrition: https://t.co/a5AShoBgYh

#FDA staff at the international mail facilities play a critical role in helping ensure foreign shipped packages don’t contain counterfeit, illicit drugs https://t.co/I6VJidNAUf

We recently tripled the number of staff we have at the International Mail Facilities to improve our ability to inspect packages that are suspected of having drugs. This front line work is critical to #FDA’s ability to protect the public health, but more w

Thank you @michaelcburgess for joining me yesterday at the International Mail Facility in New York to see firsthand the massive volume of imports arriving daily and the critical work #FDA & @CBP is doing to stop illicit, counterfeit, unapproved drugs

#FDA can and will do more to modernize & streamline our food and nutrition programs to make sure that our investments of new & existing resources achieve their intended public health goals: https://t.co/a5AShoBgYh.

RT @SGottliebFDA: @SecAzar @US_FDA It was my honor to host you today at FDA @SecAzar! Delighted to have the opportunity to showcase F… https://t.co/oy0G9LTrcb

@SecAzar @US_FDA It was my honor to host you today at FDA @SecAzar! Delighted to have the opportunity to showcase FDA’s talented staff & state-of-the-art campus. Thank you for your commitment to our mission. We value your partnership in tackling press

RT @CDCgov: New #VitalSigns report: emergency department visits for opioid overdoses are increasing. Find out how your communit… https://t.co/x17j1hyeBL

RT @DrRichBesser: https://t.co/J9yEqgF8q2 Ask the @Surgeon_General for 10 minutes to explain the U.S. health care system; he'll probably o… QT @Surgeon_General: Excited to be at @RWJF to discuss better health through better partnerships. Look forward to having a conversation… https://t.co/KmwJ8Fi2dl)

RT @SecAzar: As I said in my speech yesterday, “change is coming". Encouraged by @UHC ’s announcement today to lower #Rx costs t… https://t.co/piafmerfsV

RT @statnews: Scott Gottlieb wants to more than double the number of packages FDA inspects for illicit drugs. https://t.co/1cRjfqlQa7

RT @AP_FDAwriter: FDA chief Scott Gottlieb wants to ramp-up package inspections at international mail facilities to stem the flow of… https://t.co/oezqf7XWOK

RT @DrMarkham: A wonderful feature in @ASCO Connection on @tmprowell: How I Became an Academic Oncologist, FDA Medical Officer, &… https://t.co/V8T4HnIeR4

Kabuki drug-pricing constructs obscure profit taking across supply chain, expose consumers to higher costs and actively discourage competition. The complexity and opacity of these schemes help conceal their corrosion on system, and impact on patients. htt

My remarks at #AHIP today highlight substantial public health benefit of a competitive market for biosimilars; strong market incentives are critical to future biosimilar development in same way incentives are key for development of innovator drugs https:/

More transparent pricing signals would encourage rapid market uptake of lower cost products, and force manufacturers to better establish the real value of their products relative to price, including through innovative payment contracts. https://t.co/VfyO1

#FDA is invested in ensuring the biosimilar pathway works and facilitating a robust market for these products. We discourage practices that reduce incentive for sponsors to invest in the development of biosimilars. https://t.co/VfyO1nOt1f

If we’re not able or willing to support the development of biosimilar market as it matures then the resulting competition we seek, and that patients need, will be derailed.  https://t.co/VfyO1nOt1f

RT @CGrantWSJ: "we continue to see a backlash against these Kabuki drug-pricing constructs -- constructs that obscure profit taking across… QT @CGrantWSJ: This is a must-read speech from @SGottliebFDA https://t.co/LGjiwGYlj1)

#FDA is seeking certain administrative steps to expand the strength of our regulatory oversight in the IMFs and may seek some additional, limited resources and authorities from Congress. We’re also working closely with our partners at @CBP & @USPS as

I’m committed to having clear implementation plans for our strategic goals & objectives while being as transparent as possible about our regulatory approach to food safety & nutrition: https://t.co/a5AShoBgYh

#FDA staff at the international mail facilities play a critical role in helping ensure foreign shipped packages don’t contain counterfeit, illicit drugs https://t.co/I6VJidNAUf

We recently tripled the number of staff we have at the International Mail Facilities to improve our ability to inspect packages that are suspected of having drugs. This front line work is critical to #FDA’s ability to protect the public health, but more w

Thank you @michaelcburgess for joining me yesterday at the International Mail Facility in New York to see firsthand the massive volume of imports arriving daily and the critical work #FDA & @CBP is doing to stop illicit, counterfeit, unapproved drugs

#FDA can and will do more to modernize & streamline our food and nutrition programs to make sure that our investments of new & existing resources achieve their intended public health goals: https://t.co/a5AShoBgYh.

RT @SGottliebFDA: @SecAzar @US_FDA It was my honor to host you today at FDA @SecAzar! Delighted to have the opportunity to showcase F… https://t.co/oy0G9LTrcb

@SecAzar @US_FDA It was my honor to host you today at FDA @SecAzar! Delighted to have the opportunity to showcase FDA’s talented staff & state-of-the-art campus. Thank you for your commitment to our mission. We value your partnership in tackling press

RT @CDCgov: New #VitalSigns report: emergency department visits for opioid overdoses are increasing. Find out how your communit… https://t.co/x17j1hyeBL

RT @DrRichBesser: https://t.co/J9yEqgF8q2 Ask the @Surgeon_General for 10 minutes to explain the U.S. health care system; he'll probably o… QT @Surgeon_General: Excited to be at @RWJF to discuss better health through better partnerships. Look forward to having a conversation… https://t.co/KmwJ8Fi2dl)

RT @SecAzar: As I said in my speech yesterday, “change is coming". Encouraged by @UHC ’s announcement today to lower #Rx costs t… https://t.co/piafmerfsV

RT @statnews: Scott Gottlieb wants to more than double the number of packages FDA inspects for illicit drugs. https://t.co/1cRjfqlQa7

RT @AP_FDAwriter: FDA chief Scott Gottlieb wants to ramp-up package inspections at international mail facilities to stem the flow of… https://t.co/oezqf7XWOK

RT @DrMarkham: A wonderful feature in @ASCO Connection on @tmprowell: How I Became an Academic Oncologist, FDA Medical Officer, &… https://t.co/V8T4HnIeR4

Kabuki drug-pricing constructs obscure profit taking across supply chain, expose consumers to higher costs and actively discourage competition. The complexity and opacity of these schemes help conceal their corrosion on system, and impact on patients. htt

My remarks at #AHIP today highlight substantial public health benefit of a competitive market for biosimilars; strong market incentives are critical to future biosimilar development in same way incentives are key for development of innovator drugs https:/

More transparent pricing signals would encourage rapid market uptake of lower cost products, and force manufacturers to better establish the real value of their products relative to price, including through innovative payment contracts. https://t.co/VfyO1

#FDA is invested in ensuring the biosimilar pathway works and facilitating a robust market for these products. We discourage practices that reduce incentive for sponsors to invest in the development of biosimilars. https://t.co/VfyO1nOt1f

If we’re not able or willing to support the development of biosimilar market as it matures then the resulting competition we seek, and that patients need, will be derailed.  https://t.co/VfyO1nOt1f

RT @CGrantWSJ: "we continue to see a backlash against these Kabuki drug-pricing constructs -- constructs that obscure profit taking across… QT @CGrantWSJ: This is a must-read speech from @SGottliebFDA https://t.co/LGjiwGYlj1)